T 1348/14 (Bortezomib formulation/UNITED STATES) of 29.09.2016

European Case Law Identifier: ECLI:EP:BA:2016:T134814.20160929
Date of decision: 29 September 2016
Case number: T 1348/14
Petition for review of: -
Application number: 02709145.3
IPC class: C07F 5/02 A61P 35/00 C07F 5/04 A61P 29/00 A61K 38/05 A61K 31/69 C07K 5/078
Language of proceedings: English
Distribution: No distribution (D)
Download: Decision in English
OJ versions: No OJ links found
Other decisions for this case: -
Abstracts for this decision: -
Application title: FORMULATION OF BORONIC ACID COMPOUNDS
Applicant name: The United States of America, represented by the
Secretary, Department of Health and Human Services
Opponent name: hameln rds gmbh
Deva Holding Anonim Sirketi
LEK Pharmaceuticals d.d.
STADA Arzneimittel AG
Actavis Group PTC ehf
Synthon B.V.
Accord Healthcare, Ltd
Board: 3.3.01
Headnote: -
Relevant legal provisions: European Patent Convention Art 56Rules of procedure of the Boards of Appeal Art 12Rules of procedure of the Boards of Appeal Art 13
Keywords: Additional data, partially admitted
Inventive step (no), obvious alternative
Catchword: -
Cited cases: -
Citing cases: T 0980/19 T 2395/22

Order

For these reasons it is decided that:

The appeal is dismissed.